Borosil Scientific
- Market cap
- ₹ 942 Cr.
- P/E
- 21.2x
- P/B
- 2.13x
- 52-week range
- 96.64 – 180.8
- ROE
- 10%
- ROCE
- 12%
- Dividend yield
- 0%
- Debt / equity
- 0.02
- Sector
- Industrial Products
- Industry
- Glass - Industrial
- Listed on
- NSE, BSE
About
Borosil Scientific Limited is a manufacturer of laboratory glassware. The Company’s segments include Scientific - Laboratory Glass & equipment and Process System, Glassware, and Others. Its portfolio includes laboratory and scientific glassware, analytical vials, filter papers, laboratory instrumentation, process systems, and primary pharmaceutical packaging solutions. Its laboratory equipment, LabQuest offers a portfolio of solutions in four key application categories: nutrition and environment, life sciences, liquid handling, and an array of essential laboratory equipment. Its LabQuest products include Block Digesters, Water Baths, Hot Plate Magnetic Stirrer, and Water Distillation. It manufactures a wide range of Glass Ampoules and Tubular glass vials of United States Pharmacopeia (USP) Type I, used as primary packaging material for pharmaceutical drugs. It also manufactures glass industrial process systems, catering to the pharmaceutical, chemical, and defense sectors.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Glass - Industrial: 6 companies →Borosil Scientific against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)21.2 against a typical 18.2: pricier than most peers (1st = cheapest).4th of 6
- Sales growth+11.2% against a typical +11.2% from a year earlier.3rd of 5
- Share price, 3 months−32.2% against a typical −21.1%.5th of 6
- Size₹ 941.9 Cr. market value against a typical ₹ 618.8 Cr. (1st = largest).3rd of 6
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ / CARE A1+ | Stable | 9 Dec 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Dec 2025 | Reaffirmed | CARE A+ / CARE A1+ | — | CARE | ₹ 100 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026Upcoming | Financial Results | To consider and approve the unaudited financial results for the period ended September 30, 2026 |
| 3 Aug 2026 | Financial Results | To consider and approve the Unaudited financial results for the quarter ended Jun 30, 2026 |
| 20 May 2026 | Financial Results/Fund Raising | To consider and approve the financial results for the quarter & financial year ended March 31, 2026 and Fund Raising |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 6 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 11 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 21 May 2025 | Financial Results/Fund Raising | To consider and approve the financial results for the period ended March 31, 2025 and Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 100 | 116 | 104 | 103 | 101 | 129 | 96 | 107 | 121 | 143 | 107 |
| Expenses | 83 | 88 | 97 | 94 | 87 | 91 | 113 | 91 | 99 | 104 | 111 | 98 |
| Operating Profit | 9 | 12 | 18 | 10 | 16 | 10 | 17 | 5 | 8 | 17 | 32 | 8 |
| OPM % | 10.3% | 12.2% | 15.8% | 9.4% | 15.4% | 9.9% | 12.8% | 5.1% | 7.5% | 14.2% | 22.4% | 7.9% |
| Other Income | 1 | 1 | 1 | 2 | 2 | 2 | 3 | −4 | 2 | 1 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 6 | 8 | 15 | 7 | 12 | 7 | 14 | −4 | 5 | 13 | 29 | 6 |
| Tax % | 20.2% | 30.5% | 35.3% | 28.5% | 29.1% | 38.3% | 38.5% | 3.2% | 44.4% | 31.3% | 6.5% | 27.1% |
| Net Profit | 5 | 6 | 9 | 5 | 9 | 4 | 9 | −4 | 3 | 9 | 27 | 4 |
| EPS in Rs | — | 0.65 | 1.05 | 0.57 | 0.99 | 0.48 | 0.97 | −0.47 | 0.32 | 0.98 | 3.06 | 0.49 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 11%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 85%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Borosil Scientific | ₹ 109.95 | ₹ 942 Cr. | 21.2x | 2.1x | 10% | — |
| Hindustan Unilever | ₹ 1,820.00 | ₹ 4,27,626 Cr. | 48.2x | 10.3x | 21.5% | 16.1% |
| Marico | ₹ 764.10 | ₹ 99,347 Cr. | 63x | 26.3x | 43.1% | 13.3% |
| Godrej Consumer Products | ₹ 851.50 | ₹ 87,134 Cr. | 53.8x | 8.6x | 15.1% | 12.3% |
| Dabur India | ₹ 366.00 | ₹ 64,927 Cr. | 39.9x | 6.6x | 17.1% | 14.2% |
| Cupid | ₹ 306.50 | ₹ 41,214 Cr. | 262.4x | 61.8x | 27.3% | 30.3% |
Management
- Vinayak Madhukar Patankar
- Whole Time Director and Chief Executive Officer
- Somnath Billur
- Chief Financial Officer
- Ramavtar Sharma
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.